| Bioactivity | FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively[1]. |
| Target | EC50: 100 nM (Ebola virus), 800 nM (Rift Valley virus), 400-900 nM (Dengue Fever virus), 200 nM (HCV) and 150 nM (HIV-1) |
| Invitro | Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM[1].In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses[1]. |
| In Vivo | FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner[1]. Animal Model: |
| Name | FGI-106 |
| CAS | 501081-38-5 |
| Formula | C28H38N6 |
| Molar Mass | 458.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Aman MJ, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009 Sep;83(3):245-51. |